BioStock: Strong start for Annexin in 2024

Annexin Pharmaceuticals had a successful 2023, and the new year seems to be starting with continued success. Positive signals of effect have now been observed in the majority of patients treated in the phase II study in retinal vein occlusion. Additionally, the company emerged strengthened from an oversubscribed rights issue that added SEK 35.6 million at the turn of the year. BioStock reached out to CEO Anders Haegerstrand for a comment.

Read the article about Annexin Pharmaceuticals here:

https://www.biostock.se/en/2024/02/strong-start-for-annexin-in-2024/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/